Regulatory Disputes with HHS: When to Negotiate and When to Litigate


Access the takeaways here.

For healthcare and life sciences companies, regulatory disputes with the U.S. Department of Health and Human Services (HHS) and its operating divisions can present significant economic costs and reputational risks. Efficient resolutions of such disputes are always preferable and require an understanding of the law, the institutional relationships between the relevant HHS operating division and other parts of the Executive Branch and agency personnel. When a company cannot reach an efficient resolution through negotiation and litigation is the only option, the company must vindicate its rights in a principled way that mitigates reputation risks.

Arm in-house healthcare and life sciences lawyers with the knowledge they need to navigate regulatory disputes with HHS and its operating divisions. Learn from former senior government officials:

  • The basics of the governing legal framework, which is the Administrative Procedure Act
  • Best practices for dispute resolution through advocacy at the division level and department levels and through litigation
  • A Case Study: APA negotiation and litigation approaches with one key HHS operating division, the U.S. Food and Drug Administration (FDA)
  • Regulatory areas that may give rise to disputes in the Biden Administration

Registration Information

12:00 pm – 1:00 pm EST

Dig Deeper

Webinar / Speaking Engagements / October 18, 2021

HLTH Boston 2021

Webinar / McDermott Event / October 5 - 6, 2021

DC bio future

Virtual Event / McDermott Event / October 15, 2021

HPE New York 2021

Webinar / Speaking Engagements / September 23, 2021

Digital Front Door: Transformation to True Digital Healthcare

London, United Kingdom / Speaking Engagements / September 20-22, 2021

HBI 2021 | New Vistas, New Opportunities

Virtual Event / Speaking Engagements / September 16, 2021

Procuring for Outcomes in an Evolving NHS

Get In Touch